Antares Pharma, Inc. (the “Company”) (NYSE Amex: AIS) today announced the promotions of Robert F. Apple to Executive Vice President, CFO and President of the Parenteral Products Division, Dr. Kaushik Dave to Senior Vice President Product Development and Dr. Peter Sadowski to Senior Vice President of the Parenteral Products Division.

“Bob, Kaushik and Peter have been key members of our senior management team and have been integral in the success Antares achieved most recently with our partner Teva Pharmaceutical and the approval of our needle-free injector product for the administration of Tev-Tropin® human growth hormone,” said Paul Wotton, President and CEO of Antares.

Mr. Apple joined Antares in February 2006 as Senior Vice President and Chief Financial Officer. Prior to joining the Company, Mr. Apple held senior management positions with InKine Pharmaceutical Company were he served as Chief Operating Officer and Financial Officer. Mr. Apple holds a B.A. degree in accounting from Temple University and is a CPA.

Dr. Dave joined the company in March 2008 as Vice President, Clinical and Regulatory Affairs. Dr. Dave joined from Transave Inhalation Biotherapeutics Inc., where he was Executive Director of Clinical, Regulatory Affairs, Quality Compliance and Program Management. Dr. Dave received his pharmacy degree from University of Bath, UK and Ph.D. in Pharmaceutical Chemistry from University of Kansas. Dr. Dave also received an M.B.A. degree from the Wharton School of the University of Pennsylvania.

Dr. Sadowski has served with the Company since its inception in 2001 as Vice President, Product Development. Prior to joining Antares, Dr. Sadowski served as Manager, Product Development for GalaGen, Inc. and Vice President, Research and Development for American Biosystems, Inc. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota.

About Antares Pharma

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems.Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system, injection technology platforms including both VibexTM disposable pressure assisted auto injectors and Vision® reusable needle-free injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements related to the Company’s future financial performance, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others: that the Company may experience difficulties or delays in the initiation, progress, or completion of its clinical trials, including the phase 3 trial of Anturol, whether caused by competition, adverse events, investigative site initiation rates, patient enrolment rates, regulatory issues, or other factors; that clinical trials may not demonstrate that Anturol is both safe and effective for the treatment of patients with overactive bladder syndrome; that the safety and/or efficacy results of the phase 3 trial of Anturol may not support an application for marketing approval in the United States or any other country; that an application for marketing approval may not be accepted for review or at all by the FDA or any other regulatory authority; and that the Company may lack the financial resources and access to capital to fund clinical trials. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.